



## PH2 Pemigatinib in SDH-deficient GIST - PEMIGIST- Phase 2

ELIGIBILITY: Histologically confirmed SDH-deficient GIST, locally advanced or metastatic disease that is unresectable.

DRUG: Pemigatinib

SITE: Dana Farber Cancer Institute, Boston, MA



## DCC-3009 - Phase 1

ELIGIBILITY: 18+, Confirmed advanced/unresectable GIST with documented KIT or PDGFRA mutations. Patients must have received at least one prior approved tyrosine kinase inhibitor in the metastatic setting.

DRUG: DCC-3009

SITE: US: Nine states



## DCC-3116 - Phase 1/2

ELIGIBILITY: 18+, pathologically confirmed diagnosis of GIST with a KIT or PDGFRA mutation. Progression on at least one approved systemic regimen in the locally or metastatic setting or have documented intolerance to it. Must not have received prior ripretinib treatment.

DRUGS: Inlexisertib + ripretinib

SITE: US: Nine states  
INT: Switzerland



## StrateGIST3 - Phase 3

ELIGIBILITY: Confirmed metastatic/and or surgically unresectable GIST. Progression on or intolerance to imatinib.

DRUG: IDRX-42 or sunitinib

SITE: US: 13 states  
INT: 17 countries



## KQB198 - Phase 2

ELIGIBILITY: Unresectable or metastatic GIST, tissue confirmation of GIST, KIT or PDGFRA mutation (excluded: KIT Exon 9 and PDGFRA D842V) . Must be in the 1<sup>st</sup> line of treatment for advanced or metastatic GIST. Prior imatinib exposure is allowed if discontinued  $\geq$  1 year ago.

DRUG: KQB198 + imatinib

SITE: US: Four states (Ohio, California, Texas, Washington)

Updated 4/27/26



## KOMET-015 - Phase 1

ELIGIBILITY: 18+, Advanced or metastatic KIT mutant GIST. Patients must have had progression on imatinib.

DRUG: Ziftomenib + imatinib

SITE: US: 21 states




## MK-6482 - Phase 2

ELIGIBILITY: 12+, advanced wildtype gastrointestinal stromal tumor (wt GIST).

DRUG: Belzutifan

SITE: US & International (70 global sites)



## Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets in the Post-imatinib Second-line setting – Phase 2

ELIGIBILITY: 18+, histologic diagnosis of GIST with presence of KIT exon 17, 18, or 14, or SDHB deficient and/ or liquid biopsy. Must have unresectable or metastatic GIST and radiologic progression on imatinib.

DRUG: Regorafenib

SITE: Houston, Texas



## Surgery in GIST for Treatment, Tumor Modeling, and Genomic Analysis

ELIGIBILITY: Eligibility: 6+, confirmed GIST or clinical presentation suspicious of GIST. This is an observational study.

SITE: Bethesda, Maryland



## NN3201 - Phase 1

ELIGIBILITY: Confirmed advanced, metastatic, or unresectable GIST. Prior treatment with imatinib.

DRUG: NN3201 (Intravenous Drug)

SITE: US: Five states



Updated 4/27/26



## Expanded Access Program (EAP) to Bezuclastinib

**ELIGIBILITY:** 18+, confirmed advanced, metastatic, or unresectable GIST. Intolerant to imatinib or received prior imatinib therapy that resulted in disease progression. Patients with previous participation in a bezuclastinib clinical trial, intolerance to sunitinib, and known PDGFRA mutations or SDH-deficiency do not qualify.

**DRUG:** Bezuclastinib + sunitinib

**SITE:** US only



## IntelliGIST (UMiami) - Phase 2

**ELIGIBILITY:** 18+, Patients who have histologically confirmed metastatic or unresectable GIST. Patients may not have received prior treatment with sunitinib or regorafenib or known to be KIT wild type.

**DRUG:** Sunitinib or regorafenib

**SITE:** Miami, Florida



Visit [GISTtrials.org](https://www.gisttrials.org) for more information and additional trials.

Updated 4/27/26